Health Care · Biological Products, (No Diagnostic Substances)

CGEM Cullinan Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 178997291 filings
Russell 2000

CGEM at a glance

Cullinan Therapeutics, Inc. (CGEM, SEC CIK 1789972) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and Form 4 insider filings as recently as November 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding Cullinan Therapeutics, Inc. (CGEM) shares worth $322.6 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Michaelson Jennifer on November 5, 2026 of 4,000 shares at $12.36 per share.
  • In the last 90 days, CGEM insiders reported 0 open-market purchases ($0) and 2 open-market sales ($222K) on Form 4, a net sale of $222K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 2 sells
Net −$222K
13F holders
26 funds
$322.6M · +0 vs prior quarter
Latest 8-K
Nov 10, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, no product sales, unchanged from Q3 2025
  • R&D expense $40.2M vs $42.0M YoY, G&A $12.4M vs $13.6M
  • Best pipeline growth: CLN-978 R&D $9.8M vs $5.3M YoY
  • Cash, equivalents, and short-term investments $289.6M, long-term investments and interest receivable $24.2M
  • Operating cash outflow $127.3M, cash expected to fund operations at least twelve months, additional capital may be needed

Risk Factors

  • Newly added SEC compliance risk: non-affiliate market value exceeded $700 million on June 30, 2026
  • Reporting transition: SRC status ends after December 31, 2026, with accommodations continuing for 2027 filings
  • Regulatory burden: accelerated-filer status could require Section 404(b) auditor attestation beginning December 31, 2027
  • Financial risk: additional reporting requirements expected to increase legal, accounting and compliance costs
  • Operational risk: expanded public-company obligations could divert management attention from operations

AI summary of the CGEM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 10, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Detailed results and management commentary available in Exhibit 99.1 press release

Item EX-99.1: Item EX-99.1

  • Cash and investments $313.8M at September 30, supporting operations into 2029 under the current plan
  • Zipalertinib first-line NDA submission underway, with Cullinan eligible for $100M approval milestone and 50/50 U.S. profit share
Filed Nov 9, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Cullinan announced clinical data from Genrix’s ongoing Phase 1b/2a velinotamig trial in active, refractory moderate-to-severe SLE
  • Velinotamig represents a globally licensed, all-indication asset outside Greater China

Item 8.01: Other Events

  • Interim Phase 1b/2a data for velinotamig in refractory SLE, with 12 patients treated across three multi-dose cohorts
  • Favorable safety profile: no dose-limiting toxicities, ICANS, or Grade 3+ CRS

Item EX-99.1: Item EX-99.1

  • Interim Phase 1b/2a data support velinotamig’s autoimmune proof of concept, with meaningful disease improvement in 8 of 9 evaluable SLE patients
  • Renal signal particularly strong: 4 of 7 patients with baseline proteinuria achieved complete renal responses within 24 weeks
Filed Nov 4, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Updated CLN-049 Phase 1 dose-escalation data planned for December ASH meeting
  • Data concern relapsed or refractory AML and MDS patients

Item 8.01: Other Events

  • Phase 1 CLN-049 data in 87 relapsed/refractory AML or MDS patients support advancing the program into ongoing Phase 2 testing
  • Two-step dosing reduced CRS to 26% from 36%, with only Grade 1 or Grade 2 events

Item EX-99.1: Item EX-99.1

  • ASH presentations on December 12-15 feature updated CLN-049 Phase 1 AML/MDS data and four total posters across oncology and autoimmune programs
  • CLN-049 reports anti-leukemic activity at selected Phase 2 target doses of 6 µg/kg and 12 µg/kg

AI summaries of CGEM 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for CGEM

Don't miss the next CGEM filing

  • Alerts as it files. A push when CGEM files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut CGEM, by share count.
  • Ask anything. An AI agent that reads every CGEM filing and answers with sources.

CGEM alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Michaelson JenniferMNov 5, 2026-
Michaelson JenniferSellNov 5, 2026$12.36
Michaelson JenniferMNov 5, 2026$4.30
Michaelson JenniferMSep 8, 2026-
Michaelson JenniferMSep 8, 2026$4.30
Michaelson JenniferSellSep 8, 2026$21.57
Michaelson JenniferMAug 13, 2026-
Michaelson JenniferMAug 13, 2026$4.30

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$191.1M-$196.9M-$241.6M
Net Income-$153.2M-$167.4M-$219.9M
Balance Sheet
Total Assets$484.2M$621.8M$448.4M
Equity$453.7M$590.3M$408.7M
ROE-33.8%-28.4%-53.8%
Per Share
EPS$-3.69--
Cash Flow
Operating CF-$134.3M-$145.3M-$175.8M
CapEx$208K$0$49K

Source: XBRL data in Cullinan Therapeutics, Inc. (CGEM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate CGEM share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
CGEM shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202626$322.6M
Q2 202626$418.6M
Q1 202625$252.6M
Q4 202523$162.8M
Q3 202524$104.9M
Q2 202524$139.6M
Q1 202521$111.3M
Q4 202418$167.1M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 187 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

CGEM filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 10, 2026Analysis
8-KNov 10, 2026Analysis-
8-KNov 9, 2026Analysis-
4Nov 6, 2026--
8-KNov 4, 2026Analysis-
8-KOct 2, 2026Analysis-
8-KSep 24, 2026Analysis-
8-KSep 14, 2026Analysis-
4Sep 10, 2026--
4Aug 14, 2026--
SC 13GAug 14, 2026-
8-KAug 13, 2026Analysis-
SC 13GAug 7, 2026-
8-KAug 6, 2026Analysis-
10-QAug 6, 2026Analysis
4Jul 7, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
8-KJun 16, 2026Analysis-
8-KJun 10, 2026Analysis
8-KJun 8, 2026Analysis

Related Health Care companies

All Health Care →

CGEM SEC filings: frequently asked questions

Are CGEM insiders buying or selling?

In the last 90 days, Cullinan Therapeutics, Inc. (CGEM) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $222,000 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold CGEM stock?

As of September 30, 2026, the largest Cullinan Therapeutics, Inc. (CGEM) holders among the 13F filers tracked by SignalX were BlackRock ($81.7 million), T. Rowe Price Group ($62.8 million), Vanguard Capital Management LLC ($40.5 million), State Street Corp ($40.0 million), Dimensional Fund Advisors ($16.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did CGEM report in its latest 8-K?

Cullinan Therapeutics, Inc. (CGEM) filed an 8-K on November 10, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026.

What are the latest CGEM SEC filings?

Cullinan Therapeutics, Inc. (CGEM) filed its latest 10-K annual report on March 10, 2026, a 10-Q quarterly report on November 10, 2026, an 8-K current report on November 10, 2026 and a Form 4 insider filing on November 6, 2026.

What is CGEM's SEC CIK number?

Cullinan Therapeutics, Inc. (CGEM)'s SEC Central Index Key (CIK) is 1789972. EDGAR lists every CGEM filing under that number.

Ask anything about CGEM

The research agent reads CGEM's filings, financials, insider trades and 13F holders, then answers with sources.